These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 9181459)

  • 1. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
    Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
    Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
    Prümmer O
    Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
    Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
    Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
    Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
    J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
    Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
    Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
    Dummer R; Müller W; Nestle F; Wiede J; Dues J; Lechner W; Haubitz I; Wolf W; Bill E; Burg G
    Cancer; 1991 May; 67(9):2300-4. PubMed ID: 1901514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
    Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
    Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
    Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
    J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
    Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
    Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
    Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
    Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
    Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
    Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
    Hänninen EL; Knüver-Hopf J; Atzpodien J
    Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.